[{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Value Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Other Small Molecule","year":"2025","type":"Series E Financing","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.11,"dosageForm":"Oral Capsule","sponsorNew":"Insilico Medicine \/ Value Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Value Partners Group"}]

Find Clinical Drug Pipeline Developments & Deals for INS018 055

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The financing aims to fund the clinical development of company's lead product INS018_055. It is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.

                          Product Name : INS018_055

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 13, 2025

                          Lead Product(s) : INS018_055

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Value Partners Group

                          Deal Size : $110.0 million

                          Deal Type : Series E Financing

                          blank